New advances in the treatment of gallbladder cancer
10.3760/cma.j.cn115610-20220517-00279
- VernacularTitle:胆囊癌治疗的新进展
- Author:
Qiang LI
1
;
Hongyuan ZHOU
;
Longping MA
;
Qi ZHANG
;
Yanzhao ZHOU
;
Shuaijing LIU
Author Information
1. 天津医科大学肿瘤医院肝胆肿瘤科 国家肿瘤临床医学研究中心 天津市肿瘤防治重点实验室 天津市恶性肿瘤临床医学研究中心，天津 300060
- Keywords:
Bile tract neoplasms;
Clinical staging;
Adjuvant therapy;
Targeted therapy;
Immunotherapy
- From:
Chinese Journal of Digestive Surgery
2022;21(7):858-865
- CountryChina
- Language:Chinese
-
Abstract:
Surgery is still the first choice for the curation of early gallbladder cancer, and the surgical strategy is selected based on anatomic position of primary tumor, accurate preoperative stage, and strict indication assessment in order to achieve the optimal curative effect. However, most patients are in advanced stage or with distant metastasis at the first diagnosis, and the recurrence rate and 5-year survival rate are not satisfied even if they receive curative resection. Subsequently, it is urgent for the employment of more treatment strategies in the process management of gallbladder cancer patients, such as neoadjuvant therapy, postoperative therapy and first-line or second-line treatment of local advanced and metastatic patients. In recent years, application of molecular targeted agents and immunotherapy have brought greater hope and laid a vaster prospect for the treatment of gallbladder cancer. However, there is still lack of evidence-based medicine data on the prognostic results, and further researches are needed. By integrating the domestic and abroad new research achievements, the authors systematically summarize the current status and future trend on the management of gallbladder cancer, and hope to provide a macroscopic and systemic treatment chart, including necessary details.
